China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
ReutersFri, January 30, 2026 at 1:35 AM UTC
0
The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski
Jan 30 (Reuters) - CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related conditions.
Advertisement
AstraZeneca will obtain access to some of the programmes and platforms of the Chinese biotechnology firm's pharmaceutical in exchange for an upfront payment of $1.2 billion, it added.
(Reporting by Sherin Sunny in Bengaluru; Editing by Rashmi Aich)
Source: “AOL Breaking”
